Navigation Links
Human Genome Sciences Announces Full Presentation of Quality-of-Life Results From Phase 2b Trial of Albuferon(R) for Hepatitis C
Date:11/5/2007

ork days compared with peginterferon alfa-2a, and also achieved statistically and clinically meaningful differences in many of the SF-36 quality-of-life domains."

Key Quality-of-Life Findings from the Phase 2b Study

Working patients in all Albuferon treatment groups recorded fewer days of missed work than was observed in the peginterferon alfa-2a treatment group. All Albuferon groups showed less impairment of health-related quality of life based on SF-36 physical and mental component summary scores.

Significantly fewer working patients taking Albuferon 900 mcg every two weeks reported missing 7 days or more of work during the month prior to their treatment visits at Weeks 12 and 24, vs. patients taking peginterferon alfa- 2a. At week 12, only 4.2% of patients taking Albuferon 900 mcg every two weeks had missed 7 or more days of work the previous month, compared with 18.1% of peginterferon alfa-2a patients (p<.05). At week 24, only 5.3% of Albuferon 900-mcg patients had missed 7 or more days of work the previous month, compared with 20.3% of peginterferon alfa-2a patients (p<.05). At Week 12, working patients taking Albuferon 900-mcg every two weeks reported missing an average of 1.1 days of work during the previous month, while peginterferon alfa-2a patients reported missing an average of 4.3 work days (p<.05). At Week 24, Albuferon 900-mcg patients had missed an average of 1.6 days of work during the previous month, while peginterferon alfa-2a patients had missed an average of 4.7 work days.

At Weeks 12 and 24, the treatment group taking Albuferon 900 mcg every two weeks also reported better scores for all eight SF-36 physical and mental health domains, as well as the physical and mental summary scores, compared with peginterferon alfa-2a. Statistically significant and clinically meaningful differences were observed in the mental health, bodily pain, vitality and social functioning domains. By the Week 12 follow-up visit after the end of tre
'/>"/>

SOURCE Human Genome Sciences, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Video: New Research Discovers Independent Brain Networks Control Human Walking
2. Lpath Demonstrates Strong Safety Profile of Lead Drug Candidate, Sphingomab(TM), in Non-Human Primates
3. Enrollment Begins on Human PK Study for Medidur(TM) FA
4. Human Genome Sciences Completes Enrollment of First Phase 3 Albuferon(R) Trial Ahead of Schedule
5. Study Confirms Limited Human-To-Human Spread of Avian-Flu Virus in Indonesia in 2006
6. Lpath Demonstrates Preclinical Efficacy of Lpathomab(TM) and Initiates Humanization Process
7. Peregrine Researchers Report Data Showing Bavituximabs Potential to Shrink Human Prostate Tumors in Model of Relapsed Disease
8. Dr. Roger Kenneth Hershline PhD MD, CEO of Global Humanceuticals, Inc. Donates New HIV Drug
9. Study Shows Plasma-Derived Human Thrombin Equivalent to Bovine Thrombin in Achieving Hemostasis in Surgery
10. Tengion Launches Second Phase 2 Clinical Trial of Regenerated Human Organ
11. Flexible Medical Systems Raises $1.2M Seed Investment for Initial Human Trials
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/30/2015)... NEW YORK , March 30, 2015  Check-Cap ... diagnostics company focused on the development of a preparation-free ... screening for colorectal cancer, announced today that its CEO, ... the March 31, 2015 trading day.  Neev and Check-Cap ... to commemorate the company,s initial public offering and simultaneous ...
(Date:3/30/2015)... and ORANGEBURG, N.Y., March 30, 2015 /PRNewswire/ ... (NASDAQ: VSCI ) shareholders have voted at ... today to approve the previously announced agreement and ... "We are pleased with the outcome of ... thank both shareholder groups for approving the merger ...
(Date:3/30/2015)... , March 30, 2015  Rigrodsky & Long, P.A.: ... (NASDAQ GM: ASPX )? , Did you purchase ... , Do you think the proposed buyout price is too ... Rigrodsky & Long, P.A. announces ... of directors of Auspex Pharmaceuticals, Inc. ("Auspex" or the "Company") ...
Breaking Medicine Technology:Check-Cap to Celebrate Initial Public Offering with NASDAQ Closing Bell Ceremony on March 31, 2015 2Check-Cap to Celebrate Initial Public Offering with NASDAQ Closing Bell Ceremony on March 31, 2015 3Uroplasty and Vision-Sciences Shareholders Approve Merger Agreement 2Uroplasty and Vision-Sciences Shareholders Approve Merger Agreement 3Uroplasty and Vision-Sciences Shareholders Approve Merger Agreement 4AUSPEX PHARMACEUTICALS, INC. SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces Investigation Of Buyout 2
... Brain Resource, Ltd., (BRRZY: OTC US, BRC: ASX), developer of ... a personal heart rate monitor for managing stress, at Health 2.0 ... slow breathing at a personal best breathing rate. ... the best ways to decrease stress, but not many people know ...
... 27, 2011 Kinerase, an icon of scientific skincare development, ... in a row.  The Kinerase Restructure Firming ... 2011 Allure Best of Beauty Awards, appearing in the magazine,s ... This year, over 236 beauty products were chosen ...
Cached Medicine Technology:Brain Resource Launches MyCalmBeat Personal Stress Reduction Monitor at Health 2.0 2Brain Resource Launches MyCalmBeat Personal Stress Reduction Monitor at Health 2.0 3Kinerase Wins Allure Best of Beauty Award for 2nd Consecutive Year 2
(Date:3/30/2015)... On March 27th, 2015, 24Hr HomeCare ... inspire courage in Seth Lane, a five-year-old boy from ... SCID causes affected individuals to be susceptible to life-threatening ... allow the development of functional immune systems. Lane, ... video with his family requesting its viewers to wear ...
(Date:3/30/2015)... March 30, 2015 GenSight ®, ... is named as a leader in The Forrester Wave™: ... 2015 report. , The independent report positions GenSight as ... possible (5 out of 5) for the analytics, corporate ... which contributed to GenSight’s position in the Leaders category. ...
(Date:3/30/2015)... 2015 V/NO (Virtually No Alcohol) Wines have ... for opening/closing and for reuse. Consumers simply twist the cup, ... New Yorkers, professionals, and basically anyone can now enjoy a ... kick back socially or pair with meals at work, home, ... dealcoholized wine and that means Napa Wine grapes undergo ...
(Date:3/30/2015)... The “Orthopedic Software Market [By ... By Applications (Orthopedic Surgery, Joint Replacement, Fracture ... – Global Forecast to 2020” analyzes and ... in North America, Europe, Asia-Pacific and the ... before Buying: http://www.marketsandmarkets.com/Enquiry_Before_Buying.asp?id=94720371 , This ...
(Date:3/30/2015)... TX (PRWEB) March 30, 2015 ... been Drummond Certified™ in the second AS4 test ... Inc., the trusted leader in interoperability software testing. ... Oracle and Software AG participated in this vendor-neutral ... represents the first AS4 interoperability certifications for IBM, ...
Breaking Medicine News(10 mins):Health News:24Hr HomeCare Staff Hosts #WearYellowForSeth Campaign for Five-Year-Old Boy with Severe Combined Immunodeficiency 2Health News:GenSight Named as a Leader by Independent Research Firm in the Strategic Planning Market 2Health News:GenSight Named as a Leader by Independent Research Firm in the Strategic Planning Market 3Health News:Napa Valley Alcohol-Removed Red, White & Rosé Wines Have Launched. 2Health News:The Global Orthopedic Software Market is Expected to Reach $308.5 Million by 2020 – Report Published by MarketsandMarkets 2Health News:The Global Orthopedic Software Market is Expected to Reach $308.5 Million by 2020 – Report Published by MarketsandMarkets 3Health News:The Global Orthopedic Software Market is Expected to Reach $308.5 Million by 2020 – Report Published by MarketsandMarkets 4Health News:Latest AS4 Standard-Based Products Drummond Certified™ 2Health News:Latest AS4 Standard-Based Products Drummond Certified™ 3
... By Amanda Gardner HealthDay Reporter , WEDNESDAY, Dec. ... urged the agency to take a new look at data ... include mercury. The FDA had ruled in 2009 that ... "We need to see where the science is and if ...
... HealthDay Reporter , THURSDAY, Dec. 16 (HealthDay News) ... missing amygdala -- the part of the brain believed ... help improve treatment for post-traumatic stress disorder (PTSD) ... human study confirming that the almond-shaped structure is crucial ...
... children, their families, artists and scientists in a first ... symbiosis was established between several groups in society, leading ... Ferreira, group leader at the Instituto Gulbenkian de Cincia, ... the 10,000 euros Simbiontes Award, for his proposal to ...
... NY, December 15, 2010 There is burgeoning public ... including cardiovascular health. In a study published in the ... Medicine, investigators found that there was no independent ... hormone and cardiovascular mortality in this prospective study, the ...
... WEDNESDAY, Dec. 15 (HealthDay News) -- In a rare case, a ... longer has any detectable HIV cells in his blood following a ... But experts were quick to caution that the case does not ... As it turns out, the donor for that transplant carried a ...
... WEDNESDAY, Dec. 15 (HealthDay News) -- A ban on drop-side ... of recalls and the deaths of more than 30 infants ... by the U.S. Consumer Product Safety Commission forbids the manufacture, ... rail that moves up and down. The requirement that all ...
Cached Medicine News:Health News:FDA Panel Calls for Safety Review of Mercury in Dental Fillings 2Health News:FDA Panel Calls for Safety Review of Mercury in Dental Fillings 3Health News:Brain Anomaly Leaves Woman Without Fear 2Health News:Brain Anomaly Leaves Woman Without Fear 3Health News:Instituto Gulbenkian de Ciencia scientist wins new Portuguese award Simbiontes for cancer research 2Health News:Vitamin D and parathyroid hormone levels may not affect cardiovascular mortality 2Health News:Docs Claim Transplant Cured Man of HIV, But Experts Urge Caution 2Health News:Docs Claim Transplant Cured Man of HIV, But Experts Urge Caution 3Health News:U.S. Government Bans Drop-Side Cribs 2
... Roches patented polymerase chain reaction (PCR) technology, ... is an essential component of Roches blood ... allows minute amounts of selected unique regions ... billions of copies (that is, to detectable ...
... Continuing to lead the market in ... WAVE IABP is a whole new first ... optic technology coupled with a physiologically based ... support with unprecedented timing accuracy. Second ...
... NexES IHC, the worlds first ... staining system introduced a whole ... while combining system modularity and ... laboratory productivity. The NexES Systems ...
... a nonprofit, physician-directed organization promoting quality ... care through programs of voluntary education, ... professionals in all sizes of medical ... accreditation, quality management services, consultation in ...
Medicine Products: